The Radiation Therapy Oncology Group (RTOG) is a multi-disciplinary cancer research group committed to improving the outcome of adults afflicted with malignancies for which new therapeutic approaches to loco-regional disease are needed. The Group is organized into disease site committees and working groups, scientific core committees, and administrative committees. The Group?s clinical research efforts continue to define new standards of care for patients with a diverse range of malignancies and to contribute to the understanding of the biology of these diseases. The Group consists of both clinical and laboratory investigators from more than 260 institutions across the United States and Canada and includes nearly 90 percent of all of the National NCI-designated comprehensive and clinical cancer centers. The Group?s objectives include: 1) to improve upon the survival of patients with those common forms of cancer for which loco-regional tumor control is an important determinant of outcomes; 2) to enhance such cancer patients? quality of life by optimizing structural and functional organ preservation while improving or maintaining survival results; and 3) to pursue new initiatives in drug development, technology assessment, outcomes methodology research, combined modality integration, and translational research to advance the first two objectives. The RTOG continues as the premiere cancer research organization focused on the systematic study of novel methods of delivering radiotherapy and the translational research questions underlying such an effort. In addition, its outstanding efforts in defining new standards for combined modality therapy for patients with advanced malignancies are uniquely facilitated by the Group?s scientific and administrative infrastructure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021661-27S2
Application #
6666083
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1979-02-01
Project End
2007-12-31
Budget Start
2002-05-17
Budget End
2002-12-31
Support Year
27
Fiscal Year
2002
Total Cost
$135,118
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
City
Reston
State
VA
Country
United States
Zip Code
20191
Ulrich, Connie M; Deshmukh, Snehal; Pugh, Stephanie L et al. (2018) Attrition in NRG Oncology's Radiation-Based Clinical Trials. Int J Radiat Oncol Biol Phys 102:26-33
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Rogers, Leland; Zhang, Peixin; Vogelbaum, Michael A et al. (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35-47
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098
Lieberman, Frank S; Wang, Meihua; Robins, H Ian et al. (2018) Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162

Showing the most recent 10 out of 591 publications